gene	entrez_id	variant	disease	doid	phenotypes	drugs	evidence_type	evidence_direction	evidence_level	clinical_significance	evidence_statement	pubmed_id	citation	nct_ids	rating	evidence_status	evidence_id	variant_id	gene_id	chromosome	start	stop	reference_bases	variant_bases	representative_transcript	chromosome2	start2	stop2	representative_transcript2	ensembl_version	reference_build	variant_summary	variant_origin	last_review_date	evidence_civic_url	variant_civic_url	gene_civic_url	gene-variant
JAK2	3717	V617F	Lymphoid Leukemia	10747			Diagnostic	Supports	B	Negative	JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL).	16081687	Levine et al., 2005, Blood		4	accepted	1	64	28	9	5073770	5073770	G	T	ENST00000381652.3					75	GRCh37	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.	Somatic Mutation	2015-06-21 16:49:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/1	https://civic.genome.wustl.edu/links/variants/64	https://civic.genome.wustl.edu/links/genes/28	JAK2-V617F
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253			Diagnostic	Supports	B	Negative	GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant.	15146165	Lasota et al., 2004, Lab. Invest.		3	accepted	2	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic Mutation	2015-06-21 16:49:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/2	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38	PDGFRA-D842V
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk).	22081665	LaRochelle et al., 2011, Oncotarget		2	accepted	3	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-26 22:10:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/3	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A.	22490330	Ribeiro et al., 2012, Blood		3	accepted	4	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/4	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
JAK2	3717	V617F	Chronic Myeloid Leukemia	8552			Diagnostic	Supports	B	Positive	JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML).	16081687	Levine et al., 2005, Blood		4	accepted	5	64	28	9	5073770	5073770	G	T	ENST00000381652.3					75	GRCh37	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.	Somatic Mutation	2015-06-21 16:49:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/5	https://civic.genome.wustl.edu/links/variants/64	https://civic.genome.wustl.edu/links/genes/28	JAK2-V617F
JAK2	3717	V617F	Bone Marrow Cancer	4960			Diagnostic	Supports	B	Positive	The SNP rs10974944 in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer.	19287384	Kilpivaara et al., 2009, Nat. Genet.		4	accepted	7	64	28	9	5073770	5073770	G	T	ENST00000381652.3					75	GRCh37	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/7	https://civic.genome.wustl.edu/links/variants/64	https://civic.genome.wustl.edu/links/genes/28	JAK2-V617F
KRAS	3845	G12	Acute Leukemia	12603			Diagnostic	Supports	B	Positive	Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation.	24571676	Andrade et al., 2014, BMC Cancer		3	accepted	8	76	30	12	25398284	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic Mutation	2015-06-21 16:49:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/8	https://civic.genome.wustl.edu/links/variants/76	https://civic.genome.wustl.edu/links/genes/30	KRAS-G12
NRAS	4893	Q61	Melanoma	1909			Diagnostic	Supports	B	Positive	Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk.	23861977	Tschandl et al., 2013, PLoS ONE		3	accepted	10	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/10	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36	NRAS-Q61
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119		Daunorubicin	Predictive	Does Not Support	B	Resistance	Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	22081665	LaRochelle et al., 2011, Oncotarget		4	accepted	11	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2015-06-21 16:49:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/11	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
MAP2K1	5604	P124S	Melanoma	1909		Selumetinib (AZD6244)	Predictive	Supports	D	Resistance	A375 cells expressing MAP2K1 P124S mutation conferred an approximately 5-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1 or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.	19915144	Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	12	82	31	15	66729162	66729162	C	T	ENST00000307102.5					75	GRCh37	MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.	Somatic Mutation	2016-08-19 18:23:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/12	https://civic.genome.wustl.edu/links/variants/82	https://civic.genome.wustl.edu/links/genes/31	MAP2K1-P124S
MAP2K1	5604	Q56P	Melanoma	1909		Selumetinib (AZD6244)	Predictive	Supports	D	Resistance	A375 cells expressing MAP2K1 Q56P mutation conferred an approximately 100-fold increased resistance to selumetinib (AZD6244) induced growth inhibition when compared to untransduced cells, cells expressing wild-type MAP2K1, or cells expressing a constitutively active form. This mutation also attenuated pERK inhibition by selumetinib in these cells.	19915144	Emery et al., 2009, Proc. Natl. Acad. Sci. U.S.A.		3	accepted	13	83	31	15	66727451	66727451	A	C	ENST00000307102.5					75	GRCh37	MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.	Somatic Mutation	2016-11-07 18:43:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/13	https://civic.genome.wustl.edu/links/variants/83	https://civic.genome.wustl.edu/links/genes/31	MAP2K1-Q56P
NRAS	4893	Q61	Melanoma	1909		Vemurafenib	Predictive	Supports	B	Resistance	Vemurafenib resistance is associated with gain of Q61 mutation in NRAS.	23569304	Trunzer et al., 2013, J. Clin. Oncol.		4	accepted	14	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic Mutation	2015-06-21 16:49:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/14	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36	NRAS-Q61
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253		Imatinib	Predictive	Supports	B	Resistance	GIST cancer with D842V mutation is resistant to imatinib.	15928335	Corless et al., 2005, J. Clin. Oncol.		4	accepted	15	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic Mutation	2015-06-21 16:49:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/15	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38	PDGFRA-D842V
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253		Imatinib	Predictive	Supports	B	Resistance	While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib.	16954519	Heinrich et al., 2006, J. Clin. Oncol.		4	accepted	16	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic Mutation	2016-12-01 15:26:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/16	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38	PDGFRA-D842V
ARAF	369	S214C	Non-small Cell Lung Carcinoma	3908		Sorafenib	Predictive	Supports	C	Sensitivity/Response	In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission.	24569458	Imielinski et al., 2014, J. Clin. Invest.		2	accepted	17	10	3	X	47426121	47426121	C	G	ENST00000377045.4					75	GRCh37	ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.	Somatic Mutation	2016-02-17 19:49:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/17	https://civic.genome.wustl.edu/links/variants/10	https://civic.genome.wustl.edu/links/genes/3	ARAF-S214C
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119		Idarubicin	Predictive	Supports	B	Sensitivity/Response	Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	22081665	LaRochelle et al., 2011, Oncotarget		4	accepted	18	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2015-06-21 16:49:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/18	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
JAK2	3717	V617F	Polycythemia Vera	8997		Pegylated IFN-alpha-2a	Predictive	Supports	B	Sensitivity/Response	In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F.	16709929	Kiladjian et al., 2006, Blood		4	accepted	19	64	28	9	5073770	5073770	G	T	ENST00000381652.3					75	GRCh37	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.	Somatic Mutation	2015-06-21 16:49:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/19	https://civic.genome.wustl.edu/links/variants/64	https://civic.genome.wustl.edu/links/genes/28	JAK2-V617F
JAK2	3717	V617F	Polycythemia Vera	8997		TG101348	Predictive	Supports	D	Sensitivity/Response	TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells.	18394554	Wernig et al., 2008, Cancer Cell		3	accepted	20	64	28	9	5073770	5073770	G	T	ENST00000381652.3					75	GRCh37	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/20	https://civic.genome.wustl.edu/links/variants/64	https://civic.genome.wustl.edu/links/genes/28	JAK2-V617F
NRAS	4893	G13D	Melanoma	1909		17-AAG	Predictive	Supports	C	Sensitivity/Response	Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation.	18375819	Banerji et al., 2008, Mol. Cancer Ther.		2	accepted	21	93	36	1	115258744	115258744	C	T	ENST00000369535.4					75	GRCh37	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/21	https://civic.genome.wustl.edu/links/variants/93	https://civic.genome.wustl.edu/links/genes/36	NRAS-G13D
NRAS	4893	Q61L	Melanoma	1909		Temozolomide	Predictive	Supports	C	Sensitivity/Response	In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months.	21576590	Soon et al., 2011, Arch Dermatol		2	accepted	22	95	36	1	115256529	115256529	T	A	ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/22	https://civic.genome.wustl.edu/links/variants/95	https://civic.genome.wustl.edu/links/genes/36	NRAS-Q61L
NRAS	4893	Q61R	Melanoma	1909		Temozolomide	Predictive	Supports	C	Sensitivity/Response	In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months.	21576590	Soon et al., 2011, Arch Dermatol		2	accepted	23	96	36	1	115256529	115256529	T	C	ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/23	https://civic.genome.wustl.edu/links/variants/96	https://civic.genome.wustl.edu/links/genes/36	NRAS-Q61R
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Does Not Support	B	N/A	There is no difference in the complete remission rate of de novo AML patients with DNMT3A mutation compared to those who are wild type for DNMT3A.	22081665	LaRochelle et al., 2011, Oncotarget		4	accepted	24	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2015-06-21 16:49:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/24	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	21067377	Ley et al., 2010, N. Engl. J. Med.		4	accepted	25	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2015-06-21 16:49:39 UTC	https://civic.genome.wustl.edu/links/evidence_items/25	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
KIT	3815	D816V	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	In acute myloid leukemia patients, D816 mutation is associated with earlier relapse and poorer prognosis than wildtype KIT.	16384925	Cairoli et al., 2006, Blood		4	accepted	26	65	29	4	55599321	55599321	A	T	ENST00000288135.5					75	GRCh37	KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.	Somatic Mutation	2015-08-05 18:23:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/26	https://civic.genome.wustl.edu/links/variants/65	https://civic.genome.wustl.edu/links/genes/29	KIT-D816V
NRAS	4893	MUTATION	Colorectal Cancer	9256			Prognostic	Supports	B	Poor Outcome	Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.	24666267	Therkildsen et al., 2014, Acta Oncol		3	accepted	27	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic Mutation	2015-11-10 17:17:52 UTC	https://civic.genome.wustl.edu/links/evidence_items/27	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36	NRAS-MUTATION
BRAF	673	V600	Melanoma	1909			Diagnostic	Supports	B	Positive	BRAF mutations are associated with melanoma arising in non-chronic sun damaged skin and with superficial spreading melanoma.	21166657	Lee et al., 2011, Br. J. Dermatol.		4	accepted	30	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/30	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	DNMT3A R882 mutations were associated with older age, higher white blood cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of cytogenetically normal AML patients.	24512939	El Ghannam et al., Blood Cells Mol. Dis.		3	accepted	31	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/31	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
ALK	238	F1174L	Inflammatory Myofibroblastic Tumor	0050905		Crizotinib	Predictive	Supports	D	Resistance	Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.	21030459	Sasaki et al., 2010, Cancer Res.		3	accepted	32	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/32	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1	ALK-F1174L
ALK	238	F1174L	Non-small Cell Lung Carcinoma	3908		Crizotinib	Predictive	Supports	D	Resistance	Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.	21030459	Sasaki et al., 2010, Cancer Res.		3	accepted	33	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/33	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1	ALK-F1174L
KIT	3815	L576P	Melanoma	1909		Imatinib,Nilotinib,Sorafenib	Predictive	Supports	D	Resistance	The melanoma cell line WM3211, which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L576P mutation alters the conformation of KIT and reduces the binding affinity of imatinib.	19671763	Woodman et al., 2009, Mol. Cancer Ther.		3	accepted	34	72	29	4	55593661	55593661	T	C	ENST00000288135.5					75	GRCh37	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	Somatic Mutation	2017-05-31 00:09:59 UTC	https://civic.genome.wustl.edu/links/evidence_items/34	https://civic.genome.wustl.edu/links/variants/72	https://civic.genome.wustl.edu/links/genes/29	KIT-L576P
KRAS	3845	G12/G13	Non-small Cell Lung Carcinoma	3908		Gefitinib,Erlotinib	Predictive	Supports	B	Resistance	In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9/38 refractory vs 0/21 sensitive patients; P=0.0201).	15696205	Pao et al., 2005, PLoS Med.		3	accepted	35	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic Mutation	2018-07-25 16:35:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/35	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30	KRAS-G12/G13
NRAS	4893	Q61	Colorectal Cancer	9256		Cetuximab	Predictive	Supports	B	Resistance	Chemotherapy-refractory patients with colorectal cancer harboring NRAS mutation (primarily Q61) have a significantly lower response rate to cetuximab than patients wildtype for NRAS.	20619739	De Roock et al., 2010, Lancet Oncol.		3	accepted	36	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic Mutation	2015-06-21 16:49:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/36	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36	NRAS-Q61
ALK	238	F1174L	Neuroblastoma	769		Alectinib (CH5424802)	Predictive	Supports	D	Sensitivity/Response	CH5424802 is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.	21575866	Sakamoto et al., 2011, Cancer Cell		3	accepted	37	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/37	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1	ALK-F1174L
ALK	238	F1174L	Neuroblastoma	769		Crizotinib	Predictive	Supports	D	Sensitivity/Response	High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.	21948233	Heuckmann et al., 2011, Clin. Cancer Res.		3	accepted	38	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/38	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1	ALK-F1174L
ALK	238	R1275Q	Neuroblastoma	769		TAE684	Predictive	Supports	D	Sensitivity/Response	TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L.	18923525	George et al., 2008, Nature		3	accepted	39	9	1	2	29432664	29432664	C	T	ENST00000389048.3					75	GRCh37	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/39	https://civic.genome.wustl.edu/links/variants/9	https://civic.genome.wustl.edu/links/genes/1	ALK-R1275Q
ARAF	369	S214C	Non-small Cell Lung Carcinoma	3908		Sorafenib	Predictive	Supports	D	Sensitivity/Response	Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.	24569458	Imielinski et al., 2014, J. Clin. Invest.		3	accepted	40	10	3	X	47426121	47426121	C	G	ENST00000377045.4					75	GRCh37	ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/40	https://civic.genome.wustl.edu/links/variants/10	https://civic.genome.wustl.edu/links/genes/3	ARAF-S214C
ARAF	369	S214C	Non-small Cell Lung Carcinoma	3908		Trametinib	Predictive	Supports	D	Sensitivity/Response	Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.	24569458	Imielinski et al., 2014, J. Clin. Invest.		3	accepted	41	10	3	X	47426121	47426121	C	G	ENST00000377045.4					75	GRCh37	ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/41	https://civic.genome.wustl.edu/links/variants/10	https://civic.genome.wustl.edu/links/genes/3	ARAF-S214C
KIT	3815	L576P	Melanoma	1909		Dasatinib	Predictive	Supports	D	Sensitivity/Response	The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib.	19671763	Woodman et al., 2009, Mol. Cancer Ther.		3	accepted	42	72	29	4	55593661	55593661	T	C	ENST00000288135.5					75	GRCh37	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/42	https://civic.genome.wustl.edu/links/variants/72	https://civic.genome.wustl.edu/links/genes/29	KIT-L576P
PDGFRA	5156	D842I	Gastrointestinal Stromal Tumor	9253		Crenolanib	Predictive	Supports	D	Sensitivity/Response	In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	22745105	Heinrich et al., 2012, Clin. Cancer Res.		4	accepted	43	98	38	4	55152092	55152093	GA	AT	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/43	https://civic.genome.wustl.edu/links/variants/98	https://civic.genome.wustl.edu/links/genes/38	PDGFRA-D842I
PDGFRA	5156	D842V	Gastrointestinal Stromal Tumor	9253		Crenolanib	Predictive	Supports	D	Sensitivity/Response	In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	22745105	Heinrich et al., 2012, Clin. Cancer Res.		4	accepted	44	99	38	4	55152093	55152093	A	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/44	https://civic.genome.wustl.edu/links/variants/99	https://civic.genome.wustl.edu/links/genes/38	PDGFRA-D842V
PDGFRA	5156	D842Y	Gastrointestinal Stromal Tumor	9253		Crenolanib	Predictive	Supports	D	Sensitivity/Response	In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	22745105	Heinrich et al., 2012, Clin. Cancer Res.		4	accepted	45	100	38	4	55152092	55152092	G	T	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/45	https://civic.genome.wustl.edu/links/variants/100	https://civic.genome.wustl.edu/links/genes/38	PDGFRA-D842Y
PDGFRA	5156	I843DEL	Gastrointestinal Stromal Tumor	9253		Crenolanib	Predictive	Supports	D	Sensitivity/Response	In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib sensitivity, crenolanib showed no significant difference from imatinib in kinase activity inhibition.	22745105	Heinrich et al., 2012, Clin. Cancer Res.		3	accepted	46	101	38	4	55152095	55152097	ATC		ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic Mutation	2016-11-04 16:27:48 UTC	https://civic.genome.wustl.edu/links/evidence_items/46	https://civic.genome.wustl.edu/links/variants/101	https://civic.genome.wustl.edu/links/genes/38	PDGFRA-I843DEL
PDGFRA	5156	DI842-843VM	Gastrointestinal Stromal Tumor	9253		Crenolanib	Predictive	Supports	D	Sensitivity/Response	In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib.	22745105	Heinrich et al., 2012, Clin. Cancer Res.		4	accepted	47	102	38	4	55152093	55152097	ACATC	TCATG	ENST00000257290.5					75	GRCh37	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Somatic Mutation	2016-02-18 18:22:03 UTC	https://civic.genome.wustl.edu/links/evidence_items/47	https://civic.genome.wustl.edu/links/variants/102	https://civic.genome.wustl.edu/links/genes/38	PDGFRA-DI842-843VM
ALK	238	R1275Q	Neuroblastoma	769		TAE684	Predictive	Supports	D	Resistance	The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.	18923525	George et al., 2008, Nature		3	accepted	48	9	1	2	29432664	29432664	C	T	ENST00000389048.3					75	GRCh37	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/48	https://civic.genome.wustl.edu/links/variants/9	https://civic.genome.wustl.edu/links/genes/1	ALK-R1275Q
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Does Not Support	B	N/A	In a large cohort of AML patients (mean = 48 years), DNMT3A mutation (64.5% of which were R882) had no prognostic value on overall, relapse free and event free survival.	23632886	Gaidzik et al., 2013, Blood		3	accepted	49	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2015-06-21 16:49:40 UTC	https://civic.genome.wustl.edu/links/evidence_items/49	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Does Not Support	B	Poor Outcome	In a large cohort (n=1770) of AML patients (18-60 years old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value for overall, relapse free and event free survival. This was true for cytogenetically normal AML and the entire cohort.	23632886	Gaidzik et al., 2013, Blood		3	accepted	50	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-02-12 23:17:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/50	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Does Not Support	B	N/A	In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD.	22490330	Ribeiro et al., 2012, Blood		4	accepted	51	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/51	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
FLT3	2322	ITD	Acute Myeloid Leukemia	9119			Prognostic	Does Not Support	B	N/A	In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD.	22490330	Ribeiro et al., 2012, Blood		4	accepted	52	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/52	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24	FLT3-ITD
KIT	3815	EXON 11 MUTATION	Gastrointestinal Stromal Tumor	9253			Prognostic	Does Not Support	B	N/A	There is no significant association between wildtype KIT or KIT mutations in exon 9 or 11 in survival among GIST patients.	16551858	Wardelmann et al., 2006, Clin. Cancer Res.		3	accepted	53	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic Mutation	2015-08-05 18:28:35 UTC	https://civic.genome.wustl.edu/links/evidence_items/53	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29	KIT-EXON 11 MUTATION
NRAS	4893	MUTATION	Acute Myeloid Leukemia	9119			Prognostic	Does Not Support	B	N/A	The presence of NRAS mutation in AML patients does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death).	15951308	Bowen et al., 2005, Blood		3	accepted	56	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic Mutation	2016-06-21 19:06:50 UTC	https://civic.genome.wustl.edu/links/evidence_items/56	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36	NRAS-MUTATION
NRAS	4893	G12	Acute Myeloid Leukemia	9119			Prognostic	Does Not Support	B	N/A	NRAS mutation status does not impact overall, event-free or disease-free survival in patients with AML.	16434492	Bacher et al., 2006, Blood		3	accepted	57	92	36	1	115258747	115258748			ENST00000369535.4					75	GRCh37	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/57	https://civic.genome.wustl.edu/links/variants/92	https://civic.genome.wustl.edu/links/genes/36	NRAS-G12
KIT	3815	EXON 11 MUTATION	Melanoma	1909		Imatinib	Predictive	Supports	B	Sensitivity/Response	Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.	23775962	Hodi et al., 2013, J. Clin. Oncol.		3	accepted	58	66	29	4	55593582	55593708			ENST00000288135.5					75	GRCh37	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	Somatic Mutation	2016-10-02 15:11:12 UTC	https://civic.genome.wustl.edu/links/evidence_items/58	https://civic.genome.wustl.edu/links/variants/66	https://civic.genome.wustl.edu/links/genes/29	KIT-EXON 11 MUTATION
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Supports	A	Poor Outcome	In a large cohort of young AML patients (18-60 years old), DNMT3A R882 mutations were associated with reduced relapse free survival in the entire cohort as well as the subset of patients with cytogenetically normal AML.	23632886	Gaidzik et al., 2013, Blood		3	accepted	61	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/61	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	21067377	Ley et al., 2010, N. Engl. J. Med.		5	accepted	62	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2015-06-21 16:49:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/62	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable, cytogenetically normal AMLs.	23632886	Gaidzik et al., 2013, Blood		3	accepted	63	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/63	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation.	21067377	Ley et al., 2010, N. Engl. J. Med.		5	accepted	64	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2015-06-21 16:49:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/64	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	In cytogenetically normal AML patients, DNMT3A R882 mutations are associated with lower overall and disease free survival as compared to patients with wild type DNMT3A.	24512939	El Ghannam et al., Blood Cells Mol. Dis.		5	accepted	65	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2015-06-21 16:49:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/65	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	In older cytogenetically normal AML patients (>59 years), DNMT3A R882 mutation is prognostic for shorter disease free survival and overall survival compared to patients without the mutation.	22291079	Marcucci et al., 2012, J. Clin. Oncol.		4	accepted	66	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2015-06-21 16:49:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/66	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3.	22490330	Ribeiro et al., 2012, Blood		4	accepted	67	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/67	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations other than R882 are prognostic for shorter disease free survival and overall survival compared to patients without the mutation.	22291079	Marcucci et al., 2012, J. Clin. Oncol.		4	accepted	68	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2015-06-21 16:49:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/68	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
FLT3	2322	ITD	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation.	21067377	Ley et al., 2010, N. Engl. J. Med.		5	accepted	69	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic Mutation	2015-06-21 16:49:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/69	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24	FLT3-ITD
KIT	3815	EXON 14 MUTATION	Gastrointestinal Stromal Tumor	9253			Prognostic	Supports	B	Poor Outcome	GIST patients with exon 14 KIT mutations had reduced overall survival compared to patients wiltype for KIT.	16551858	Wardelmann et al., 2006, Clin. Cancer Res.		3	accepted	70	69	29	4	55595501	55595651			ENST00000288135.5					75	GRCh37	c-KIT exon 14 mutations lie within the tyrosine kinase domain of the protein. While relatively rare in primary gastrointestinal tumors, they are notably more prevalent in refractory disease, suggesting a role in imatinib resistance. Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/70	https://civic.genome.wustl.edu/links/variants/69	https://civic.genome.wustl.edu/links/genes/29	KIT-EXON 14 MUTATION
NRAS	4893	MUTATION	Melanoma	1909			Prognostic	Supports	B	Poor Outcome	In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS.	22180178	Jakob et al., 2012, Cancer		3	accepted	71	208	36	1	115247090	115259515			ENST00000369535.4					75	GRCh37		Somatic Mutation	2016-06-21 19:08:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/71	https://civic.genome.wustl.edu/links/variants/208	https://civic.genome.wustl.edu/links/genes/36	NRAS-MUTATION
BRAF	673	V600E+V600M	Melanoma	1909		Dabrafenib	Predictive	Supports	C	Sensitivity/Response	A single patient with BRAF V600E/V600M bi-allelic mutation responded to the V600E drug dabrafenib.	23031422	Ponti et al., 2012, J Hematol Oncol		3	accepted	73	13	5	7	140453135	140453137			ENST00000288602.6					75	GRCh37	A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response.	Somatic Mutation	2016-02-17 19:49:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/73	https://civic.genome.wustl.edu/links/variants/13	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E+V600M
RET	5979	M918T	Thyroid Medullary Carcinoma	3973			Diagnostic	Supports	B	Positive	In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases.	18073307	Elisei et al., 2008, J. Clin. Endocrinol. Metab.		5	accepted	74	113	42	10	43617416	43617416	T	C	ENST00000355710.3					75	GRCh37	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Somatic Mutation	2015-06-21 16:49:41 UTC	https://civic.genome.wustl.edu/links/evidence_items/74	https://civic.genome.wustl.edu/links/variants/113	https://civic.genome.wustl.edu/links/genes/42	RET-M918T
RET	5979	C634W	Thyroid Medullary Carcinoma	3973		Motesanib	Predictive	Supports	D	Resistance	Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET.	21422803	Coxon et al., 2012, J. Endocrinol. Invest.		3	accepted	75	112	42	10	43609950	43609950	C	G	ENST00000355710.3					75	GRCh37	RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/75	https://civic.genome.wustl.edu/links/variants/112	https://civic.genome.wustl.edu/links/genes/42	RET-C634W
RET	5979	M918T	Thyroid Medullary Carcinoma	3973		Motesanib	Predictive	Supports	D	Resistance	Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET.	21422803	Coxon et al., 2012, J. Endocrinol. Invest.		3	accepted	76	113	42	10	43617416	43617416	T	C	ENST00000355710.3					75	GRCh37	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/76	https://civic.genome.wustl.edu/links/variants/113	https://civic.genome.wustl.edu/links/genes/42	RET-M918T
RET	5979	M918T	Thyroid Medullary Carcinoma	3973		AZD1480	Predictive	Supports	D	Sensitivity/Response	The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.	23056499	Couto et al., 2012, PLoS ONE		3	accepted	77	113	42	10	43617416	43617416	T	C	ENST00000355710.3					75	GRCh37	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/77	https://civic.genome.wustl.edu/links/variants/113	https://civic.genome.wustl.edu/links/genes/42	RET-M918T
RET	5979	M918T	Thyroid Medullary Carcinoma	3973			Prognostic	Supports	B	Poor Outcome	Compared to those who harbor a wild type RET, patients with RET M918T mutation develop larger and more aggressive medullary thyroid cancer.	9839497	Egawa et al., 1998, Jpn. J. Clin. Oncol.		4	accepted	78	113	42	10	43617416	43617416	T	C	ENST00000355710.3					75	GRCh37	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Somatic Mutation	2015-06-21 16:49:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/78	https://civic.genome.wustl.edu/links/variants/113	https://civic.genome.wustl.edu/links/genes/42	RET-M918T
BRAF	673	V600E	Thyroid Cancer	1781			Diagnostic	Supports	B	Positive	BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer.	21594703	Howell et al., 2011, Ann. Surg. Oncol.		3	accepted	79	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/79	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Thyroid Cancer	1781			Diagnostic	Supports	B	Positive	Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.	24570209	Crescenzi et al., 2014, Horm. Metab. Res.		5	accepted	80	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2015-06-21 16:49:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/80	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Melanoma	1909		Dacarbazine,Temozolomide	Predictive	Does Not Support	B	N/A	BRAF status does not predict outcome in patients treated with dacarbazine or temozolomide.	24586605	Meckbach et al., 2014, PLoS ONE		2	accepted	82	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2017-05-31 02:12:38 UTC	https://civic.genome.wustl.edu/links/evidence_items/82	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
PIK3CA	5290	E542K	Colorectal Cancer	9256		Regorafenib	Predictive	Does Not Support	B	N/A	PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment.	24559322	Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther		4	accepted	83	103	37	3	178936082	178936082	G	A	ENST00000263967.3					75	GRCh37	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with other PIK3CA variants or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/83	https://civic.genome.wustl.edu/links/variants/103	https://civic.genome.wustl.edu/links/genes/37	PIK3CA-E542K
BRAF	673	V600E	Melanoma	1909		Trametinib,PD0325901	Predictive	Does Not Support	D	Resistance	In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors.	24576830	Nissan et al., 2014, Cancer Res.		3	accepted	86	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2016-02-18 18:20:58 UTC	https://civic.genome.wustl.edu/links/evidence_items/86	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
KRAS	3845	EXON 2 MUTATION	Colorectal Cancer	9256		Regorafenib	Predictive	Does Not Support	B	Sensitivity/Response	KRAS mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment.	24559322	Sartore-Bianchi et al., 2014, Expert Rev Anticancer Ther		4	accepted	87	75	30	12	25398208	25398329			ENST00000256078.4					75	GRCh37	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/87	https://civic.genome.wustl.edu/links/variants/75	https://civic.genome.wustl.edu/links/genes/30	KRAS-EXON 2 MUTATION
BRAF	673	V600	Colorectal Cancer	9256		Panitumumab	Predictive	Supports	B	Resistance	In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone).	23325582	Peeters et al., 2013, Clin. Cancer Res.		3	accepted	88	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/88	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600
BRAF	673	V600E	Colorectal Cancer	9256		Sorafenib,Panitumumab	Predictive	Supports	D	Sensitivity/Response	Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.	19001320	Di Nicolantonio et al., 2008, J. Clin. Oncol.		3	accepted	89	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2017-09-16 01:20:46 UTC	https://civic.genome.wustl.edu/links/evidence_items/89	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Melanoma	1909		Vemurafenib	Predictive	Supports	D	Resistance	In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors.	24576830	Nissan et al., 2014, Cancer Res.		3	accepted	90	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/90	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Non-small Cell Lung Carcinoma	3908		Dabrafenib	Predictive	Supports	C	Resistance	In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib.	23524406	Rudin et al., 2013, J Thorac Oncol		2	accepted	91	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2016-02-17 19:49:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/91	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E AMPLIFICATION	Colorectal Cancer	9256		Selumetinib (AZD6244)	Predictive	Supports	E	Resistance	COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF V600E gene.	21098728	Corcoran et al., 2010, Sci Signal		4	accepted	92	14	5	7	140434279	140624564			ENST00000288602.6					75	GRCh37	Amplification of BRAF V600E has been shown to confer resistance to MEK inhibitors. For more information on the V600 locus, see the V600E entry.	Somatic Mutation	2016-07-13 23:41:33 UTC	https://civic.genome.wustl.edu/links/evidence_items/92	https://civic.genome.wustl.edu/links/variants/14	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E AMPLIFICATION
BRAF	673	V600	Melanoma	1909		Dabrafenib,Trametinib	Predictive	Supports	B	Sensitivity/Response	Melanoma patients with BRAF V600E/K mutations had longer progression-free survival, increased tumor regression,  and increased duration of response to combined dabrafenib and trametinib treatment compared to dabrafenib alone.	23020132	Flaherty et al., 2012, N. Engl. J. Med.		3	accepted	93	17	5	7	140453136	140453137			ENST00000288602.6					75	GRCh37	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Somatic Mutation	2017-05-31 02:11:15 UTC	https://civic.genome.wustl.edu/links/evidence_items/93	https://civic.genome.wustl.edu/links/variants/17	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600
BRAF	673	V600D	Melanoma	1909		Dabrafenib	Predictive	Supports	B	Sensitivity/Response	Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.	23463675	Ponti et al., 2013, J. Clin. Pathol.		5	accepted	94	11	5	7	140453135	140453136	CA	AT	ENST00000288602.6					75	GRCh37	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	Somatic Mutation	2015-06-21 16:49:42 UTC	https://civic.genome.wustl.edu/links/evidence_items/94	https://civic.genome.wustl.edu/links/variants/11	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600D
BRAF	673	V600E	Melanoma	1909		Dabrafenib,Trametinib	Predictive	Supports	B	Sensitivity/Response	Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma.	24583796	Menzies et al., 2014, Clin. Cancer Res.		5	accepted	95	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2016-02-18 21:13:57 UTC	https://civic.genome.wustl.edu/links/evidence_items/95	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Colorectal Cancer	9256		PLX4720,GDC0941	Predictive	Supports	D	Sensitivity/Response	Combined MEK inhibitor GDC0941 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation.	23845441	Rad et al., 2013, Cancer Cell		3	accepted	96	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2017-05-31 15:38:49 UTC	https://civic.genome.wustl.edu/links/evidence_items/96	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Colorectal Cancer	9256		PLX4720,Nutlin-3	Predictive	Supports	D	Sensitivity/Response	Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy.	23812671	Ji et al., 2013, Clin. Cancer Res.		2	accepted	97	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2017-05-31 00:11:36 UTC	https://civic.genome.wustl.edu/links/evidence_items/97	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Colorectal Cancer	9256		Capecitabine,Vemurafenib,Bevacizumab	Predictive	Supports	D	Sensitivity/Response	Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased survival and reduced tumor burden compared to single and double agent therapies.	22180495	Yang et al., 2012, Cancer Res.		2	accepted	98	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2017-05-31 15:36:21 UTC	https://civic.genome.wustl.edu/links/evidence_items/98	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Colorectal Cancer	9256		Vemurafenib	Predictive	Supports	D	Sensitivity/Response	Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation.	22180495	Yang et al., 2012, Cancer Res.		2	accepted	99	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/99	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Thyroid Cancer	1781			Prognostic	Does Not Support	B	Poor Outcome	Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer.	24354346	Walczyk et al., 2014, Clin. Endocrinol. (Oxf)		5	accepted	102	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2015-06-21 16:49:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/102	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Colorectal Cancer	9256			Prognostic	Supports	B	Poor Outcome	V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as a marker of poor prognosis.	24594804	Chen et al., 2014, PLoS ONE		5	accepted	103	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2018-07-17 22:57:55 UTC	https://civic.genome.wustl.edu/links/evidence_items/103	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Melanoma	1909			Prognostic	Supports	B	Poor Outcome	BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.	24388723	Nagore et al., 2014, J. Am. Acad. Dermatol.		3	accepted	104	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2015-06-21 16:49:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/104	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Thyroid Cancer	1781			Prognostic	Supports	B	Poor Outcome	BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.	21594703	Howell et al., 2011, Ann. Surg. Oncol.		3	accepted	105	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2015-06-21 16:49:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/105	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Thyroid Cancer	1781			Prognostic	Supports	B	Poor Outcome	BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.	24396464	He et al., 2014, Oncol Lett		3	accepted	106	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2015-06-21 16:49:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/106	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
BRAF	673	V600E	Thyroid Cancer	1781			Prognostic	Supports	B	Poor Outcome	V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).	21594703	Howell et al., 2011, Ann. Surg. Oncol.		3	accepted	107	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2015-06-21 16:49:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/107	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119			Diagnostic	Does Not Support	B	Positive	NPM1 mutations were not associated with the M3 acute myeloid leukemia FAB subtype (0/55).	16455956	Thiede et al., 2006, Blood		3	accepted	108	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2015-06-21 16:49:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/108	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	W288FS	Acute Myeloid Leukemia	9119			Diagnostic	Does Not Support	B	Positive	No NPM1 mutations were identified in patients with favorable risk cytogenetics (79/215 patients).	21067377	Ley et al., 2010, N. Engl. J. Med.		4	accepted	109	87	35	5	170837547	170837548		TCTG	ENST00000517671.1					75	GRCh37	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/109	https://civic.genome.wustl.edu/links/variants/87	https://civic.genome.wustl.edu/links/genes/35	NPM1-W288FS
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Negative	Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients.	23632886	Gaidzik et al., 2013, Blood		3	accepted	110	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/110	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Negative	NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid leukemia.	16076867	Schnittger et al., 2005, Blood		4	accepted	111	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2015-06-21 16:49:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/111	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes.	21067377	Ley et al., 2010, N. Engl. J. Med.		5	accepted	112	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/112	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype).	21067377	Ley et al., 2010, N. Engl. J. Med.		4	accepted	113	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/113	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients.	23632886	Gaidzik et al., 2013, Blood		3	accepted	114	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/114	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients.	23632886	Gaidzik et al., 2013, Blood		3	accepted	115	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/115	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119			Diagnostic	Supports	A	Positive	AML with mutated NPM1 is a provisional entity in the World Health Organization (WHO) classification of acute myeloid leukemia (AML). This mutation should be tested for in clinical trials and is recommended for testing in patients with cytogentically normal AML.	19357394	Vardiman et al., 2009, Blood		5	accepted	116	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2016-07-01 17:25:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/116	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	NPM1 mutations were associated with de novo AML as well as M4 and M5 FAB subtypes.	17957027	Gale et al., 2008, Blood		2	accepted	117	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/117	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	NPM1 mutations were associated with M4, M5a and M5b FAB subtypes of acute myeloid leukemia.	16076867	Schnittger et al., 2005, Blood		4	accepted	118	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2015-06-21 16:49:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/118	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	NPM1 mutations were associated with M5a and M5b FAB subtypes of acute myeloid leukemia.	16455956	Thiede et al., 2006, Blood		3	accepted	119	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/119	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	NPM1 mutations were associated with normal karyotype in older (>60) patients.	19059939	Schlenk et al., 2009, Haematologica		3	accepted	120	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/120	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	W288FS	Acute Myeloid Leukemia	9119			Diagnostic	Supports	B	Positive	NPM1 mutations were associated with intermediate risk cytogenetics (including normal karyotype).	21067377	Ley et al., 2010, N. Engl. J. Med.		4	accepted	121	87	35	5	170837547	170837548		TCTG	ENST00000517671.1					75	GRCh37	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/121	https://civic.genome.wustl.edu/links/variants/87	https://civic.genome.wustl.edu/links/genes/35	NPM1-W288FS
CEBPA	1050	MUTATION	Acute Myeloid Leukemia	9119		All-trans Retinoic Acid	Predictive	Does Not Support	B	Sensitivity/Response	In a randomized trial of previously untreated younger (<60) patients with acute myeloid leukemia (excluding acute promyelocytic leukemia) and high-risk myelodysplastic syndrome CEBPA mutation status had no significant impact on patient response to ATRA (N=20) compared to randomized control (N=15).	19965647	Burnett et al., 2010, Blood		3	accepted	122	29	15	19	33790840	33793470			ENST00000498907.2					75	GRCh37	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	Somatic Mutation	2016-02-25 20:53:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/122	https://civic.genome.wustl.edu/links/variants/29	https://civic.genome.wustl.edu/links/genes/15	CEBPA-MUTATION
PIK3CA	5290	EXON 10 MUTATION	Colorectal Cancer	9256		Cetuximab	Predictive	Does Not Support	B	N/A	In chemotherapy-refractory patients with colorectal cancer, Exon 9 PIK3CA mutations (Exon 9) had no significant impact on response rate, disease control rate, progression free surivival or overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA.	20619739	De Roock et al., 2010, Lancet Oncol.		3	accepted	123	106	37	3	178935998	178936122			ENST00000263967.3					75	GRCh37	PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.	Somatic Mutation	2015-08-14 16:03:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/123	https://civic.genome.wustl.edu/links/variants/106	https://civic.genome.wustl.edu/links/genes/37	PIK3CA-EXON 10 MUTATION
NRAS	4893	Q61	Colorectal Cancer	9256		Cetuximab	Predictive	Does Not Support	B	Resistance	In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61) was not informative for disease control rate, progression free survival or overall survival following cetuximab plus chemotherapy.	20619739	De Roock et al., 2010, Lancet Oncol.		3	accepted	124	94	36	1	115256528	115256530			ENST00000369535.4					75	GRCh37	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.	Somatic Mutation	2015-06-21 16:49:43 UTC	https://civic.genome.wustl.edu/links/evidence_items/124	https://civic.genome.wustl.edu/links/variants/94	https://civic.genome.wustl.edu/links/genes/36	NRAS-Q61
ALK	238	F1174L	Neuroblastoma	769		Crizotinib	Predictive	Supports	D	Resistance	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation. The authors conclude that this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors.	22072639	Bresler et al., 2011, Sci Transl Med		3	accepted	125	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic Mutation	2017-10-19 15:58:24 UTC	https://civic.genome.wustl.edu/links/evidence_items/125	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1	ALK-F1174L
BRAF	673	V600E	Colorectal Cancer	9256		Cetuximab	Predictive	Supports	B	Resistance	Chemotherapy-refractory patients with colorectal cancer harboring BRAF mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype BRAF.	20619739	De Roock et al., 2010, Lancet Oncol.		3	accepted	126	12	5	7	140453136	140453136	A	T	ENST00000288602.6					75	GRCh37	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/126	https://civic.genome.wustl.edu/links/variants/12	https://civic.genome.wustl.edu/links/genes/5	BRAF-V600E
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		All-trans Retinoic Acid	Predictive	Supports	B	Resistance	ATRA treatment did not effect overall survival in patients <60 years old with FLT3-ITD mutation.	19965647	Burnett et al., 2010, Blood		3	accepted	127	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/127	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24	FLT3-ITD
FLT3	2322	ITD	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	FLT3-ITD mutation without NPM1 was associated with increased relapse risk and reduced overall survival in young adult AML patients (median age 43).	17957027	Gale et al., 2008, Blood		4	accepted	128	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/128	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24	FLT3-ITD
FLT3	2322	ITD	Acute Myeloid Leukemia	9119			Prognostic	Supports	B	Poor Outcome	Increasing level of FLT3-ITD mutant correlated with reduced disease-free and overall survival as well as increased relapse rate.	17957027	Gale et al., 2008, Blood		3	accepted	129	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic Mutation	2016-03-16 22:09:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/129	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24	FLT3-ITD
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		Daunorubicin	Predictive	Supports	D	Resistance	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.	15626738	Bagrintseva et al., 2005, Blood		3	accepted	130	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/130	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24	FLT3-ITD
FLT3	2322	ITD	Acute Myeloid Leukemia	9119		SU5614	Predictive	Supports	D	Resistance	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.	15626738	Bagrintseva et al., 2005, Blood		3	accepted	131	55	24	13	28608219	28608351			ENST00000241453.7					75	GRCh37	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/131	https://civic.genome.wustl.edu/links/variants/55	https://civic.genome.wustl.edu/links/genes/24	FLT3-ITD
KRAS	3845	G12/G13	Colorectal Cancer	9256		Cetuximab	Predictive	Supports	B	Resistance	Chemotherapy-refractory patients with colorectal cancer harboring KRAS mutations (primarily G12/G13) had lower response and disease control rates and shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype KRAS.	20619739	De Roock et al., 2010, Lancet Oncol.		3	accepted	134	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/134	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30	KRAS-G12/G13
KRAS	3845	G12/G13	Colorectal Cancer	9256		Cetuximab	Predictive	Supports	D	Resistance	KRAS mutations were significantly associated with lack of response to cetuximab in patients with advanced colorectal cancer.	18202412	Livre et al., 2008, J. Clin. Oncol.		3	accepted	135	77	30	12	25398280	25398285			ENST00000256078.4					75	GRCh37	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/135	https://civic.genome.wustl.edu/links/variants/77	https://civic.genome.wustl.edu/links/genes/30	KRAS-G12/G13
KRAS	3845	G12V	Colorectal Cancer	9256		Cetuximab	Predictive	Supports	D	Resistance	Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.	20978259	De Roock et al., 2010, JAMA		4	accepted	136	425	30	12	25398284	25398284	C	A	ENST00000256078.4					75	GRCh37	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions	Somatic Mutation	2016-09-27 17:34:47 UTC	https://civic.genome.wustl.edu/links/evidence_items/136	https://civic.genome.wustl.edu/links/variants/425	https://civic.genome.wustl.edu/links/genes/30	KRAS-G12V
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		All-trans Retinoic Acid	Predictive	Supports	B	Resistance	ATRA treatment did not effect overall survival in patients <60 years old with NPM1 mutation regardless of FLT3-ITD status.	19965647	Burnett et al., 2010, Blood		3	accepted	137	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/137	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
PIK3CA	5290	EXON 21 MUTATION	Colorectal Cancer	9256		Cetuximab	Predictive	Supports	B	Resistance	Chemotherapy-refractory patients with colorectal cancer harboring Exon 20 PIK3CA mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype PIK3CA.	20619739	De Roock et al., 2010, Lancet Oncol.		3	accepted	138	105	37	3	178951882	178952495			ENST00000263967.3					75	GRCh37	PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/138	https://civic.genome.wustl.edu/links/variants/105	https://civic.genome.wustl.edu/links/genes/37	PIK3CA-EXON 21 MUTATION
WT1	7490	EXON 7 MUTATION	Acute Myeloid Leukemia	9119		Daunorubicin,Cytarabine	Predictive	Supports	B	Resistance	WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML.	18591546	Virappane et al., 2008, J. Clin. Oncol.		3	accepted	139	129	49	11	32417803	32417953			ENST00000332351.3					75	GRCh37	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/139	https://civic.genome.wustl.edu/links/variants/129	https://civic.genome.wustl.edu/links/genes/49	WT1-EXON 7 MUTATION
ALK	238	EML4-ALK L1196M	Non-small Cell Lung Carcinoma	3908		Alectinib (CH5424802)	Predictive	Supports	D	Sensitivity/Response	CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or EML4-ALK with the L1196M mutation.	21575866	Sakamoto et al., 2011, Cancer Cell		3	accepted	141	7	1	2	29443631	29443631	G	T	ENST00000389048.3					75	GRCh37	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, L1196M has been shown to confer resistance to crizotinib. This was also true in a patient with both EML4-ALK C1156Y & L1196M.	Somatic Mutation	2016-06-29 21:04:30 UTC	https://civic.genome.wustl.edu/links/evidence_items/141	https://civic.genome.wustl.edu/links/variants/7	https://civic.genome.wustl.edu/links/genes/1	ALK-EML4-ALK L1196M
ALK	238	F1174L	Neuroblastoma	769		TAE684	Predictive	Supports	D	Sensitivity/Response	SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition.	18923525	George et al., 2008, Nature		4	accepted	142	8	1	2	29443695	29443695	G	T	ENST00000389048.3					75	GRCh37	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/142	https://civic.genome.wustl.edu/links/variants/8	https://civic.genome.wustl.edu/links/genes/1	ALK-F1174L
ALK	238	R1275Q	Neuroblastoma	769		Crizotinib	Predictive	Supports	D	Sensitivity/Response	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.	22072639	Bresler et al., 2011, Sci Transl Med		3	accepted	143	9	1	2	29432664	29432664	C	T	ENST00000389048.3					75	GRCh37	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/143	https://civic.genome.wustl.edu/links/variants/9	https://civic.genome.wustl.edu/links/genes/1	ALK-R1275Q
FGFR3	2261	FGFR3-BAIAP2L1	Bladder Carcinoma	4007		PD173074	Predictive	Supports	D	Sensitivity/Response	Following identification of this fusion in a patient, this fusion was expressed in HEK 293T cells leading to oligomerization in the absence of ligand, induced morphologic changes in the cell and increased cellular proliferation consistent with FGFR activation. Mouse xenografts using the bladder cell line SW780 which harbors an FGFR3-BAIAP2L1 fusion showed reduced tumor burden when treated with the FGFR inhibitor PD173074.	23558953	Wu et al., 2013, Cancer Discov		3	accepted	144	53	23	4	1795039	1810599			ENST00000340107.4	7	97991744	97920963	ENST00000005260.8	75	GRCh37	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/144	https://civic.genome.wustl.edu/links/variants/53	https://civic.genome.wustl.edu/links/genes/23	FGFR3-FGFR3-BAIAP2L1
KRAS	3845	G13D	Colorectal Cancer	9256		Cetuximab	Predictive	Supports	D	Sensitivity/Response	Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.	20978259	De Roock et al., 2010, JAMA		4	accepted	145	81	30	12	25398281	25398281	C	T	ENST00000256078.4					75	GRCh37	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.	Somatic Mutation	2016-03-16 22:09:26 UTC	https://civic.genome.wustl.edu/links/evidence_items/145	https://civic.genome.wustl.edu/links/variants/81	https://civic.genome.wustl.edu/links/genes/30	KRAS-G13D
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		All-trans Retinoic Acid	Predictive	Supports	B	Sensitivity/Response	ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD.	19059939	Schlenk et al., 2009, Haematologica		2	accepted	146	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/146	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		Daunorubicin	Predictive	Supports	B	Sensitivity/Response	Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11.	22417203	Patel et al., 2012, N. Engl. J. Med.		2	accepted	147	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2015-06-21 16:49:44 UTC	https://civic.genome.wustl.edu/links/evidence_items/147	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		Valproic Acid	Predictive	Supports	B	Sensitivity/Response	For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid.	24797300	Tassara et al., 2014, Blood		2	accepted	148	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/148	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		All-trans Retinoic Acid,NSC348884	Predictive	Supports	D	Sensitivity/Response	NSC348884 combined with ATRA treatment induces apoptosis in primary AML cells harboring mutant NPM1 but not in cells with wildtype NPM1 or both mutant NPM1 and FLT3-ITD.	21719597	Balusu et al., 2011, Blood		3	accepted	149	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2017-05-31 15:38:16 UTC	https://civic.genome.wustl.edu/links/evidence_items/149	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		Anti-CD33,Anti-CD123	Predictive	Supports	E	Sensitivity/Response	CD33 and CD123 expression was significantly increased in patients with NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33 and anti-CD123 therapy.	24927407	Ehninger et al., 2014, Blood Cancer J		2	accepted	150	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2016-03-16 22:09:25 UTC	https://civic.genome.wustl.edu/links/evidence_items/150	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	EXON 12 MUTATION	Acute Myeloid Leukemia	9119		Anti-CD33	Predictive	Supports	E	Sensitivity/Response	CD33 expression was significantly increased in patients with NPM1 mutation with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy.	24927407	Ehninger et al., 2014, Blood Cancer J		2	accepted	151	86	35	5	170837531	170837569			ENST00000517671.1					75	GRCh37	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/151	https://civic.genome.wustl.edu/links/variants/86	https://civic.genome.wustl.edu/links/genes/35	NPM1-EXON 12 MUTATION
NPM1	4869	W288FS	Acute Myeloid Leukemia	9119		NSC348884	Predictive	Supports	D	Sensitivity/Response	NSC348884 induced apoptosis in OPI-AML3 cells harboring an NPM1 mutation.	21719597	Balusu et al., 2011, Blood		3	accepted	152	87	35	5	170837547	170837548		TCTG	ENST00000517671.1					75	GRCh37	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/152	https://civic.genome.wustl.edu/links/variants/87	https://civic.genome.wustl.edu/links/genes/35	NPM1-W288FS
NPM1	4869	W288FS	Acute Myeloid Leukemia	9119		Induction Therapy	Predictive	Supports	E	Sensitivity/Response	NPM1 mutation (Type A, W288fs) causes cytoplasmic localization of NPM when transfected into a non-hematopoietic cell line (293T cells). Cytoplasmic localization of NPM in AML patients was associated with good response to induction therapy.	15659725	Falini et al., 2005, N. Engl. J. Med.		3	accepted	153	87	35	5	170837547	170837548		TCTG	ENST00000517671.1					75	GRCh37	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	Somatic Mutation	2015-06-21 16:49:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/153	https://civic.genome.wustl.edu/links/variants/87	https://civic.genome.wustl.edu/links/genes/35	NPM1-W288FS
TSC1	7248	FRAMESHIFT TRUNCATION	Non-small Cell Lung Carcinoma	3908		Rapamycin (Sirolimus)	Predictive	Supports	D	Sensitivity/Response	Following rapamycin treatment of mice with KrasG12D-induced lung tumors, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, increased apoptosis, reduced proliferation and reduced tumor burden compared to Tsc1 wildtype mice.	19966866	Liang et al., 2010, Oncogene		3	accepted	154	124	46	9	135766735	135820008			ENST00000298552.3					75	GRCh37	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	Somatic Mutation	2016-02-17 19:50:06 UTC	https://civic.genome.wustl.edu/links/evidence_items/154	https://civic.genome.wustl.edu/links/variants/124	https://civic.genome.wustl.edu/links/genes/46	TSC1-FRAMESHIFT TRUNCATION
TSC1	7248	LOSS-OF-FUNCTION	Bladder Carcinoma	4007		Everolimus	Predictive	Supports	B	Sensitivity/Response	Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts.	22923433	Iyer et al., 2012, Science		3	accepted	155	125	46	9	135766735	135820008			ENST00000298552.3					75	GRCh37	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	Somatic Mutation	2015-06-21 16:49:45 UTC	https://civic.genome.wustl.edu/links/evidence_items/155	https://civic.genome.wustl.edu/links/variants/125	https://civic.genome.wustl.edu/links/genes/46	TSC1-LOSS-OF-FUNCTION
FLT3	2322	MUTATION	Acute Myeloid Leukemia	9119			Prognostic	Does Not Support	B	N/A	FLT3 mutations did not alter overall survival or remission duration in younger (16-60), cytogenetically normal AML patients with CEBPA mutations. 10/36 patients with CEBPA mutations also had FLT3 mutations (8 FLT3-ITD, 2 FLT3-D835).	14726504	Frhling et al., 2004, J. Clin. Oncol.		2	accepted	156	519	24	13	28577411	28674729			ENST00000241453.7					75	GRCh37		Somatic Mutation	2016-04-12 22:51:01 UTC	https://civic.genome.wustl.edu/links/evidence_items/156	https://civic.genome.wustl.edu/links/variants/519	https://civic.genome.wustl.edu/links/genes/24	FLT3-MUTATION
DNMT3A	1788	R882	Acute Myeloid Leukemia	9119			Prognostic	Does Not Support	B	N/A	Complete remission rates did not differ between patients with wildtype or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML.	22291079	Marcucci et al., 2012, J. Clin. Oncol.		4	accepted	157	32	18	2	25457241	25457243			ENST00000264709.3					75	GRCh37	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.	Somatic Mutation	2016-03-16 22:09:27 UTC	https://civic.genome.wustl.edu/links/evidence_items/157	https://civic.genome.wustl.edu/links/variants/32	https://civic.genome.wustl.edu/links/genes/18	DNMT3A-R882
